IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v125y2021i10p1297-1304.html
   My bibliography  Save this article

Payments reported by the pharmaceutical industry in Ireland from 2015 to 2019: An observational study

Author

Listed:
  • Moriarty, Frank
  • Larkin, James
  • Fahey, Tom

Abstract

Background: The pharmaceutical industry makes large numbers of payments to healthcare organisations (HCOs) and healthcare professionals (HCPs). Ireland has a large pharmaceutical industry presence and national debate on legislating for greater industry payment transparency. This study characterises payments in Ireland to HCPs and HCOs during 2015–2019, and the content, consistency and methodology of the data source.

Suggested Citation

  • Moriarty, Frank & Larkin, James & Fahey, Tom, 2021. "Payments reported by the pharmaceutical industry in Ireland from 2015 to 2019: An observational study," Health Policy, Elsevier, vol. 125(10), pages 1297-1304.
    • Handle: RePEc:eee:hepoli:v:125:y:2021:i:10:p:1297-1304
    DOI: 10.1016/j.healthpol.2021.07.016
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168851021002013
    Download Restriction: Full text for ScienceDirect subscribers only
    File URL: https://libkey.io/10.1016/j.healthpol.2021.07.016?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Ozaki, Akihiko & Saito, Hiroaki & Senoo, Yuki & Sawano, Toyoaki & Shimada, Yuki & Kobashi, Yurie & Yamamoto, Kana & Suzuki, Yosuke & Tanimoto, Tetsuya, 2020. "Overview and transparency of non-research payments to healthcare organizations and healthcare professionals from pharmaceutical companies in Japan: Analysis of payment data in 2016," Health Policy, Elsevier, vol. 124(7), pages 727-735.
    2. ., 2021. "Article 192(1) TFEU vs Article 192(2) TFEU," Chapters, in: Including Consumption in Emissions Trading, chapter 5, pages 96-117, Edward Elgar Publishing.
    3. Mulinari, Shai & Martinon, Luc & Jachiet, Pierre-Alain & Ozieranski, Piotr, 2021. "Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries," Health Policy, Elsevier, vol. 125(7), pages 915-922.
    4. Hneine Brax & Racha Fadlallah & Lina Al-Khaled & Lara A Kahale & Hala Nas & Fadi El-Jardali & Elie A Akl, 2017. "Association between physicians’ interaction with pharmaceutical companies and their clinical practices: A systematic review and meta-analysis," PLOS ONE, Public Library of Science, vol. 12(4), pages 1-28, April.
    5. Holbrook, Anne & Lexchin, Joel & Pullenayegum, Eleanor & Campbell, Craig & Marlow, Bernard & Troyan, Sue & Weijer, Charles & Blackmer, Jeff & Brazil, Kevin & Willison, Don, 2013. "What do Canadians think about physician–pharmaceutical industry interactions?," Health Policy, Elsevier, vol. 112(3), pages 255-263.
    6. Shanti Gamper-Rabindran & Stephen Finger, 2013. "Does industry self-regulation reduce pollution? Responsible Care in the chemical industry," Journal of Regulatory Economics, Springer, vol. 43(1), pages 1-30, January.
    7. Grundy, Quinn & Habibi, Roojin & Shnier, Adrienne & Mayes, Christopher & Lipworth, Wendy, 2018. "Decoding disclosure: Comparing conflict of interest policy among the United States, France, and Australia," Health Policy, Elsevier, vol. 122(5), pages 509-518.
    8. Rickard, Emily & Ozieranski, Piotr & Mulinari, Shai, 2019. "Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK," Health Policy, Elsevier, vol. 123(12), pages 1244-1250.
    9. Susan L Norris & Haley K Holmer & Lauren A Ogden & Brittany U Burda & Rongwei Fu, 2013. "Conflicts of Interest among Authors of Clinical Practice Guidelines for Glycemic Control in Type 2 Diabetes Mellitus," PLOS ONE, Public Library of Science, vol. 8(10), pages 1-1, October.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Mulinari, Shai & Pashley, Dylan & Ozieranski, Piotr, 2022. "Advancing international comparison of pharmaceutical industry funding of patient advocacy: Focus on Denmark," Health Policy, Elsevier, vol. 126(12), pages 1256-1262.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Anju Murayama & Yuki Senoo & Kayo Harada & Yasuhiro Kotera & Hiroaki Saito & Toyoaki Sawano & Yosuke Suzuki & Tetsuya Tanimoto & Akihiko Ozaki, 2022. "Awareness and Perceptions among Members of a Japanese Cancer Patient Advocacy Group Concerning the Financial Relationships between the Pharmaceutical Industry and Physicians," IJERPH, MDPI, vol. 19(6), pages 1-24, March.
    2. Mulinari, Shai & Martinon, Luc & Jachiet, Pierre-Alain & Ozieranski, Piotr, 2021. "Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries," Health Policy, Elsevier, vol. 125(7), pages 915-922.
    3. Charles Sabel & Gary Herrigel & Peer Hull Kristensen, 2018. "Regulation under uncertainty: The coevolution of industry and regulation," Regulation & Governance, John Wiley & Sons, vol. 12(3), pages 371-394, September.
    4. Shai Mulinari & Andreas Vilhelmsson & Emily Rickard & Piotr Ozieranski, 2020. "Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs," PLOS ONE, Public Library of Science, vol. 15(6), pages 1-19, June.
    5. Eszter Saghy & Shai Mulinari & Piotr Ozieranski, 2021. "Drug company payments to General Practices in England: Cross-sectional and social network analysis," PLOS ONE, Public Library of Science, vol. 16(12), pages 1-16, December.
    6. Marcel Probst & Caspar Sauter, 2015. "CO2 Emissions and Greenhouse Gas Policy Stringency - An Empirical Assessment," IRENE Working Papers 15-03, IRENE Institute of Economic Research.
    7. Christian Dienes, 2015. "Energy and Material Efficiency Improvements, Compliance Strategies, and Investments in Resource Efficiency: A Cross-Country Study," Schumpeter Discussion Papers SDP15004, Universitätsbibliothek Wuppertal, University Library.
    8. Rachel Thompson & Zoe Paskins & Barry G. Main & Thaddeus Mason Pope & Evelyn C. Y. Chan & Ben W. Moulton & Michael J. Barry & Clarence H. Braddock III, 2021. "Addressing Conflicts of Interest in Health and Medicine: Current Evidence and Implications for Patient Decision Aid Development," Medical Decision Making, , vol. 41(7), pages 768-779, October.
    9. Li, Huan & Khanna, Neha & Vidovic, Martina, 2014. "Third Party Certification and Self-Regulation: Evidence from Responsible Care and Accidents in the US Chemical Industry," 2014 Annual Meeting, July 27-29, 2014, Minneapolis, Minnesota 170492, Agricultural and Applied Economics Association.
    10. Ray Moynihan & Brooke Nickel & Jolyn Hersch & Elaine Beller & Jenny Doust & Shane Compton & Alexandra Barratt & Lisa Bero & Kirsten McCaffery, 2015. "Public Opinions about Overdiagnosis: A National Community Survey," PLOS ONE, Public Library of Science, vol. 10(5), pages 1-13, May.
    11. Harada, Kayo & Ozaki, Akihiko & Saito, Hiroaki & Sawano, Toyoaki & Yamamoto, Kana & Murayama, Anju & Senoo, Yuki & Tanimoto, Tetsuya, 2021. "Financial payments made by pharmaceutical companies to the authors of Japanese hematology clinical practice guidelines between 2016 and 2017," Health Policy, Elsevier, vol. 125(3), pages 320-326.
    12. Emily Rickard & Piotr Ozieranski, 2021. "A hidden web of policy influence: The pharmaceutical industry’s engagement with UK’s All-Party Parliamentary Groups," PLOS ONE, Public Library of Science, vol. 16(6), pages 1-20, June.
    13. Anju Murayama & Akihiko Ozaki & Hiroaki Saito & Toyoaki Sawano & Yuki Shimada & Kana Yamamoto & Yosuke Suzuki & Tetsuya Tanimoto, 2020. "Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan," PLOS ONE, Public Library of Science, vol. 15(10), pages 1-16, October.
    14. Ansari, Bahareh, 2021. "Industry payments and physicians prescriptions: Effect of a payment restriction policy," Social Science & Medicine, Elsevier, vol. 278(C).
    15. Li, Huan & Khanna, Neha, 2016. "Does Voluntary Regulation Provide Regulatory Relief? A Lesson from the Responsible Care Program," 2016 Annual Meeting, July 31-August 2, Boston, Massachusetts 235652, Agricultural and Applied Economics Association.
    16. Daniel Matisoff, 2015. "Sources of specification errors in the assessment of voluntary environmental programs: understanding program impacts," Policy Sciences, Springer;Society of Policy Sciences, vol. 48(1), pages 109-126, March.
    17. Livio Garattini & Anna Padula, 2019. "Conflict of interest disclosure: striking a balance?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(5), pages 633-636, July.
    18. Light, Donald W. & Lexchin, Joel R., 2021. "Pharmaceuticals as a market for “lemons”: Theory and practice," Social Science & Medicine, Elsevier, vol. 268(C).
    19. Hoang, Phi Cong & McGuire, William & Prakash, Aseem, 2018. "Reducing Toxic Chemical Pollution in Response to Multiple Information Signals: The 33/50 Voluntary Program and Toxicity Disclosures," Ecological Economics, Elsevier, vol. 146(C), pages 193-202.
    20. Martina Vidovic & Michael S. Delgado & Neha Khanna, 2019. "Third‐Party Certification And The Effectiveness Of Voluntary Pollution Abatement Programs: Evidence From Responsible Care," Economic Inquiry, Western Economic Association International, vol. 57(4), pages 1751-1770, October.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:125:y:2021:i:10:p:1297-1304. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.